{Reference Type}: Case Reports
{Title}: Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
{Author}: Hagihara Y;Suetsugu T;Uto H;Kozono T;Masada Y;Satozono Y;Shinmura M;Koreeda Y;Mizuno K;Inoue H;
{Journal}: Respir Investig
{Volume}: 62
{Issue}: 1
{Year}: 2024 Jan 3
暂无{DOI}: 10.1016/j.resinv.2023.09.006
{Abstract}: Osimertinib has demonstrated efficacy as the first- and second-line treatment for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. However, EGFR-mutant NSCLC cells often acquire resistance to osimertinib. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation (BRAF V600E) was detected in a re-biopsy (LC-SCRUM-TRY testing) of a patient with advanced lung adenocarcinoma who was resistant to osimertinib treatment. Currently, the patient is receiving dabrafenib/trametinib combination therapy and is under observation; a slight shrinking effect of cancer has been observed.